Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BOSTON SCIENTIFIC CORPORATION Boston Scientific Corporation Stock price
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 56.14 USD | +0.45% | +0.92% | +21.33% | |
| Nov. 27 | Global markets live: Novo Nordisk, HSBC, Amazon, Tesla, Huawei... |  |
| Nov. 27 | Canaccord Genuity Adjusts Price Target on Boston Scientific to $64 From $60, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2023 * | 14.11 B | Sales 2024 * | 15.30 B | Capitalization | 82.24 B |
|---|---|---|---|---|---|
| Net income 2023 * | 1,528 M | Net income 2024 * | 2,082 M | EV / Sales 2023 * | 6,31x |
| Net Debt 2023 * | 6,787 M | Net Debt 2024 * | 4,455 M | EV / Sales 2024 * | 5,67x |
| P/E ratio 2023 * | 53,7x | P/E ratio 2024 * | 38,2x | Employees | 45,000 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 84.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.45% | ||
| 1 week | +0.92% | ||
| Current month | +0.45% | ||
| 1 month | +6.89% | ||
| 3 months | +4.70% | ||
| 6 months | +8.34% | ||
| Current year | +21.33% |
1 week
54.91
56.22
1 month
50.8456.22
Current year
44.3556.22
1 year
44.3556.22
3 years
33.4256.22
5 years
24.1056.22
10 years
11.1056.22
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 58 | 2011 |
Daniel Brennan
DFI | Director of Finance/CFO | 57 | 1995 |
Jodi Eddy
CTO | Chief Tech/Sci/R&D Officer | 50 | 2015 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Wichmann
BRD | Director/Board Member | 60 | 2021 |
| Director/Board Member | 68 | 2015 | |
Edward Ludwig
BRD | Director/Board Member | 71 | 2014 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.23% | 1 M€ | -13.95% | ||
| 6.04% | 131 M€ | -2.21% | ||
| 5.66% | 89 M€ | -3.57% | - | |
| 5.40% | 48 M€ | -4.26% | - | |
| 4.90% | 820 M€ | -4.74% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 56.14 | +0.45% | 4,730,456 |
| 23-11-30 | 55.89 | +0.81% | 8,346,178 |
| 23-11-29 | 55.44 | +0.93% | 4,780,411 |
| 23-11-28 | 54.93 | -1.36% | 6,450,749 |
| 23-11-27 | 55.69 | +0.11% | 5,313,739 |
Delayed Quote Nyse, December 01, 2023 at 04:00 pm EST
More quotes
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (61.5%): products used in cardiology surgeries (28.4% of net sales), cardiac rhythm management (26.8%), peripheral surgeries (24.2%), electrophysiology tests (7.5%) and other (13.1%);
- endodontic surgery (31.3%): equipment used in endoscopy (55.6% of net sales) and urology (44.4%);
- neuromodulation (7.2%).
The United States account for 60.2% of net sales.
Calendar
2024-01-30
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
56.14USD
Average target price
60.12USD
Spread / Average Target
+7.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.33% | 82 244 M $ | |
| -9.91% | 192 B $ | |
| -15.80% | 165 B $ | |
| +18.83% | 111 B $ | |
| +13.76% | 64 424 M $ | |
| -8.19% | 49 148 M $ | |
| -8.38% | 41 460 M $ | |
| -13.94% | 37 623 M $ | |
| +18.89% | 31 598 M $ | |
| -23.30% | 23 482 M $ |
